Market Research Logo

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015’, provides an overview of the Dry (Atrophic) Macular Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dry (Atrophic) Macular Degeneration Overview
Therapeutics Development
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dry (Atrophic) Macular Degeneration - Products under Development by Companies
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development
Aciont Inc.
Acucela Inc.
Alexion Pharmaceuticals, Inc.
Alimera Sciences, Inc.
Apellis Pharmaceuticals, Inc.
Benitec Biopharma Limited
Catalyst Biosciences, Inc.
Cell Cure Neurosciences, Ltd.
Foamix Pharmaceuticals Ltd.
Genentech, Inc.
GenSight Biologics SA
GlaxoSmithKline Plc
Icon Bioscience, Inc.
MacuCLEAR, Inc.
Novartis AG
Ocata Therapeutics, Inc.
Ophthotech Corp.
pSivida Corp.
R-Tech Ueno, Ltd.
StemCells, Inc.
Sun Pharma Advanced Research Company Ltd.
U.S. Stem Cell, Inc.
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AdipoCell - Drug Profile
Mechanism of Action
R&D Progress
APL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLG-561 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fluocinolone acetonide SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Ocular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-030 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-933776 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMR-59 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HuCNS-SC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICR-14967 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lampalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MA09-hRPE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MC-1101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OCU-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONL-1204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OpRegen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OpRegen Plus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RC-1 Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RST-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Amyloid Beta for Glaucoma and Dry AMD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TT-231 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
unoprostone isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dry (Atrophic) Macular Degeneration - Recent Pipeline Updates
Dry (Atrophic) Macular Degeneration - Dormant Projects
Dry (Atrophic) Macular Degeneration - Discontinued Products
Dry (Atrophic) Macular Degeneration - Product Development Milestones
Featured News & Press Releases
Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN
Jul 20, 2015: StemCells Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration
Dec 17, 2013: Bioheart Announces Clinical Study for Dry Macular Degeneration
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN
Oct 01, 2013: Roche to present data on Lampalizumab at investor event
Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration
Apr 18, 2013: StemCells Adds Byers Eye Institute At Stanford As Second Site For Phase I/II Clinical Trial In Dry Age-related Macular Degeneration
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference
Oct 04, 2012: StemCells Announces First Transplant Of Neural Stem Cells Into Patient In Phase I/II Study For Dry Age-related Macular Degeneration
Jun 21, 2012: StemCells Initiates Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2015
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Acucela Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Ocata Therapeutics, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by R-Tech Ueno, Ltd., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by StemCells, Inc., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Dry (Atrophic) Macular Degeneration - Pipeline by U.S. Stem Cell, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Dry (Atrophic) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2015
Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2015
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2015
Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2015
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report